Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised SEB in connection with an issue of additional Tier 1 captial of MUSD 600
Mandate

Vinge has advised SEB in connection with an issue of additional Tier 1 captial of MUSD 600

March 27, 2017 Capital Markets and Public M&A

Vinge has advised Skandinaviska Enskilda Banken AB (publ) (“SEB”) as to Swedish law in connection with the bank’s issue of Additional Tier 1 Capital in the amount of MUSD 600 in the form of a debt instrument with no final maturity and with automatically conversion into Class A-shares if the CET1 ratio of the bank decreases to a certain level.

The instrument is listed on the Global Exchange Market regulated by the Irish Stock Exchange.

SEB issued the Additional Tier 1 Capital to refinance an old similar instrument that reaches its call date later this year and to optimize its capital structure.

Vinge’s team consisted mainly of Göran Nyström, Charlotte Levin, Albert Wållgren and Malte Hedlund.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024